API
Doxofylline
KDMF APIs
Doxofylline
Korean name | 독소필린 |
|---|---|
Category | Respiratory organs |
CAS No. | 69975-86-6 |
KDMF registration No. | 20181029-209-J-98 |
Manufacturer | Ami Lifesciences Private Limited. |
Specification | In-house |
Product information
IUPAC Name | 7-[(1,3-dioxolan-2-yl)methyl]-1,3-dimethyl-2,3,6,7-tetrahydro-1H-purine-2,6-dione |
|---|---|
Synonyms | Doxophylline |
Description | Doxofylline is a methylxanthine derivative with the presence of a dioxolane group in position 7. As a drug used in the treatment of asthma, doxofylline has shown similar efficacy to theophylline but with significantly fewer side effects in animal and human studies. In contrast with other xanthine derivatives, doxofylline does not significantly bind to adenosine alpha-1 or alpha-2 receptors and lacks stimulating effects. Decreased affinity for adenosine receptors may account for the better safety profile of doxofylline compared to theophylline . Unlike theophylline, doxofylline does not affect calcium influx and does not antagonize the actions of calcium channel blockers which could explain reduced cardiac adverse reactions associated with the drug. The anti-asthmatic effects of doxophylline are mediated by other mechanisms, primarily through inhibiting the activities of the phosphodiesterase (PDE) enzyme. |
Certificate of Analysis | If you need more information, please contact us. |
If you need additional documents such as specifications or certificates of analysis, please request them together with your inquiry. Our team will review and reply. (02-579-1056 · ace@acebiopharm.com)